{"id":75357,"date":"2026-08-19T17:23:15","date_gmt":"2026-08-19T09:23:15","guid":{"rendered":"https:\/\/flcube.com\/?p=75357"},"modified":"2026-08-19T17:23:16","modified_gmt":"2026-08-19T09:23:16","slug":"lepu-medicals-sirna-drug-mwn117-wins-nmpa-clinical-trial-approval-for-overweight-and-obesity-inhbe-targeting-therapy-shows-synergy-potential-with-glp-1-agonists","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75357","title":{"rendered":"Lepu Medical&#8217;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lepu Medical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300003:SHE\">SHE: 300003<\/a>) announced that <strong>MWN117 injection<\/strong> has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical trials for the treatment of <strong>overweight or obesity<\/strong>, advancing a novel <strong>siRNA\u2011based approach<\/strong> in one of pharmaceutical&#8217;s hottest therapeutic arenas.<\/p>\n\n\n\n<h2 id=\"h-approval-summary\" class=\"wp-block-heading\">Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Lepu Medical (SHE: 300003)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Shanghai Minwei Biotechnology Co., Ltd. (Lepu subsidiary)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>MWN117 injection<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>siRNA therapeutic targeting <strong>INHBE<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Overweight or obesity<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Clinical trial approval granted by <strong>NMPA<\/strong><\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-mwn117\" class=\"wp-block-heading\">Drug Profile \u2013 MWN117<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> <strong>siRNA drug<\/strong> independently developed by <strong>Shanghai Minwei Biotechnology<\/strong>, a subsidiary of Lepu Medical<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>INHBE<\/strong>, a member of the <strong>TGF\u2011\u03b2 superfamily<\/strong> specifically expressed in <strong>hepatocytes<\/strong><\/li>\n\n\n\n<li><strong>Target Biology:<\/strong> INHBE is associated with <strong>inhibiting lipolysis, promoting fat storage, and inducing insulin resistance<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> MWN117 reduces lipid accumulation by <strong>downregulating INHBE gene expression<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-highlights\" class=\"wp-block-heading\">Preclinical Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Observation in Animal Models<\/th><\/tr><\/thead><tbody><tr><td><strong>Body Fat Percentage<\/strong><\/td><td>Significantly reduced<\/td><\/tr><tr><td><strong>Visceral Fat<\/strong><\/td><td>Significantly reduced<\/td><\/tr><tr><td><strong>Muscle Mass<\/strong><\/td><td>Increased<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>Expected synergistic effects with <strong>GLP\u20111 receptor agonists<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The muscle\u2011sparing profile is notable: a key criticism of current GLP\u20111\u2011based weight\u2011loss therapies is concurrent lean\u2011mass loss, positioning MWN117&#8217;s muscle\u2011mass increase as a potential differentiator.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beyond GLP\u20111 Monotherapy:<\/strong> The obesity drug market is rapidly evolving toward combination strategies; MWN117&#8217;s expected <strong>synergy with GLP\u20111 receptor agonists<\/strong> could make it an attractive add\u2011on asset addressing body composition quality, not just weight reduction.<\/li>\n\n\n\n<li><strong>siRNA in Metabolic Disease:<\/strong> An <strong>INHBE\u2011targeting siRNA<\/strong> leverages the growing validation of RNA interference in metabolic indications, with hepatocyte\u2011specific expression potentially supporting liver\u2011targeted delivery and differentiated safety.<\/li>\n\n\n\n<li><strong>Strategic Pivot Signal:<\/strong> For <strong>Lepu Medical<\/strong>, primarily known for cardiovascular devices, an obesity siRNA program signals expansion into chronic metabolic disease therapeutics with a potentially large addressable market in China.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> First\u2011in\u2011human trial design and safety\/tolerability readouts, early body\u2011composition data, and future combination studies pairing MWN117 with GLP\u20111 receptor agonists.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory outcomes, and commercial expectations for MWN117. Actual results may differ due to risks including early\u2011stage clinical uncertainty, regulatory decisions, and competitive dynamics in obesity therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN117\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN117\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-6a3aba46-a9af-4893-861a-38891b281aea\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN117\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN117\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN117\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6a3aba46-a9af-4893-861a-38891b281aea\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China&#8217;s National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,374,64,864],"class_list":["post-75357","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-lepu-medical-technology","tag-rnai-aso","tag-she-300003"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu Medical&#039;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical&#039;s hottest therapeutic arenas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75357\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical&#039;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists\" \/>\n<meta property=\"og:description\" content=\"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical&#039;s hottest therapeutic arenas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75357\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T09:23:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T09:23:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical&#8217;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists\",\"datePublished\":\"2026-08-19T09:23:15+00:00\",\"dateModified\":\"2026-08-19T09:23:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Lepu Medical Technology\",\"RNAi \\\/ ASO\",\"SHE: 300003\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75357#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75357\",\"name\":\"Lepu Medical's siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T09:23:15+00:00\",\"dateModified\":\"2026-08-19T09:23:16+00:00\",\"description\":\"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical's hottest therapeutic arenas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75357\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75357#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical&#8217;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical's siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical's hottest therapeutic arenas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75357","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical's siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists","og_description":"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical's hottest therapeutic arenas.","og_url":"https:\/\/flcube.com\/?p=75357","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T09:23:15+00:00","article_modified_time":"2026-08-19T09:23:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75357#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75357"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical&#8217;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists","datePublished":"2026-08-19T09:23:15+00:00","dateModified":"2026-08-19T09:23:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75357"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Lepu Medical Technology","RNAi \/ ASO","SHE: 300003"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75357#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75357","url":"https:\/\/flcube.com\/?p=75357","name":"Lepu Medical's siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T09:23:15+00:00","dateModified":"2026-08-19T09:23:16+00:00","description":"Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA\u2011based approach in one of pharmaceutical's hottest therapeutic arenas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75357#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75357"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75357#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical&#8217;s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity \u2013 INHBE\u2011Targeting Therapy Shows Synergy Potential with GLP\u20111 Agonists"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75357"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75357\/revisions"}],"predecessor-version":[{"id":75359,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75357\/revisions\/75359"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}